MX362793B - Vacuna acelular contra pertussis. - Google Patents

Vacuna acelular contra pertussis.

Info

Publication number
MX362793B
MX362793B MX2015011879A MX2015011879A MX362793B MX 362793 B MX362793 B MX 362793B MX 2015011879 A MX2015011879 A MX 2015011879A MX 2015011879 A MX2015011879 A MX 2015011879A MX 362793 B MX362793 B MX 362793B
Authority
MX
Mexico
Prior art keywords
acellular pertussis
pertussis vaccine
fim
pertussis
acellular
Prior art date
Application number
MX2015011879A
Other languages
English (en)
Other versions
MX2015011879A (es
Inventor
Theunis Poolman Jan
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MX2015011879A publication Critical patent/MX2015011879A/es
Publication of MX362793B publication Critical patent/MX362793B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una composición de vacuna acelular contra pertussis (aP) que comprende los antígenos para Bordetella pertussis toxoide de pertussis (PT), hemaglutinina filamentosa (FHA) y fimbrias tipos 2 y 3 (FIM), y opcionalmente pertactina (PRN), donde FIM está presente en una cantidad de 12-100 µg por dosis para humanos.
MX2015011879A 2013-03-08 2014-03-06 Vacuna acelular contra pertussis. MX362793B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361774993P 2013-03-08 2013-03-08
EP13169328 2013-05-27
PCT/EP2014/054379 WO2014135651A1 (en) 2013-03-08 2014-03-06 Acellular pertussis vaccine

Publications (2)

Publication Number Publication Date
MX2015011879A MX2015011879A (es) 2016-01-08
MX362793B true MX362793B (es) 2019-02-13

Family

ID=48470836

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011879A MX362793B (es) 2013-03-08 2014-03-06 Vacuna acelular contra pertussis.

Country Status (22)

Country Link
US (2) US8916173B2 (es)
EP (1) EP2863943B1 (es)
JP (1) JP6282673B2 (es)
KR (1) KR102236498B1 (es)
CN (1) CN105007936B (es)
AP (1) AP2015008702A0 (es)
AU (1) AU2014224556B2 (es)
BR (1) BR112015021523A8 (es)
CA (1) CA2903937C (es)
CL (1) CL2015002513A1 (es)
DK (1) DK2863943T3 (es)
EA (1) EA030749B1 (es)
ES (1) ES2597832T3 (es)
IL (1) IL241271A (es)
MX (1) MX362793B (es)
MY (1) MY172181A (es)
NZ (1) NZ630868A (es)
PE (1) PE20151720A1 (es)
PH (1) PH12015501875A1 (es)
SG (1) SG11201506858SA (es)
TW (1) TWI630915B (es)
WO (1) WO2014135651A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2596919C2 (ru) * 2015-01-16 2016-09-10 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка
RU2626532C2 (ru) * 2015-01-16 2017-07-28 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
KR102426041B1 (ko) 2017-08-01 2022-07-29 주식회사 녹십자 냉동 및 해동 과정을 포함하는 백일해균 유래 단백질 수득 방법
KR102362777B1 (ko) 2018-03-27 2022-02-15 주식회사 녹십자 친화성 크로마토그래피 공정을 포함하는 백일해균 유래 단백질 수득 방법
EP3876982A1 (en) 2018-11-06 2021-09-15 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
CN111053898B (zh) * 2019-12-26 2023-05-16 北京科兴中维生物技术有限公司 一种疫苗组合物及其应用
JP2023517330A (ja) * 2020-03-09 2023-04-25 ダイナヴァックス テクノロジーズ コーポレイション 破傷風、ジフテリア、および百日咳に対する能動的追加免疫付与
WO2024064579A1 (en) * 2022-09-20 2024-03-28 Ohio State Innovation Foundation Immunogenic proteins from bordetella pertussis

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4525349A (en) 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
GB8412207D0 (en) 1984-05-12 1984-06-20 Wellcome Found Antigenic preparations
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
GB8516442D0 (en) 1985-06-28 1985-07-31 Wellcome Found Cloned antigen
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3528006A1 (de) 1985-08-05 1987-02-05 Degussa Verfahren zur herstellung von epoxidierten organosiliziumverbindungen
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
GB8601279D0 (en) 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
DE3781541T2 (de) 1986-12-23 1993-05-06 Univ Leland Stanford Junior Modifiziertes pertussistoxin.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0299108B1 (en) 1987-07-17 1994-05-18 Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH DNA-molecules coding for FMDH control regions and structured gene for a protein having FMDH-activity and their uses
US7144576B1 (en) 1987-09-04 2006-12-05 Amgen, Inc. Modified pertussis toxin
KR0168039B1 (ko) 1987-09-04 1999-01-15 로버트 디. 웨스트 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
IT1223334B (it) 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8807860D0 (en) 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA1341123C (en) 1988-10-27 2000-10-17 David A. Relman Filamentous hemagglutinin of b. pertussis
US5101014A (en) 1989-02-10 1992-03-31 United States Of America Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
DE69022106T2 (de) 1989-04-28 1996-02-15 Sclavo Spa Pertussistoxin-Mutanten, dieselbe produzierende Bordetella-Stämme und ihre Verwendung als Vakzin gegen Pertussis.
GB8910570D0 (en) 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
GB8914122D0 (en) 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
DE69025375T2 (de) 1989-11-06 1996-08-01 Smithkline Beecham Biolog Verfahren
US5276142A (en) 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
CY1935A (en) 1990-02-12 1991-02-07 Smithkline Beecham Biolog Novel vaccine and method therefor
GB9007657D0 (en) 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
EP0484621A3 (en) 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US6444211B2 (en) 1991-04-03 2002-09-03 Connaught Laboratories, Inc. Purification of a pertussis outer membrane protein
AU662783B2 (en) 1992-01-08 1995-09-14 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Whooping cough vaccine
DE69324487T2 (de) 1992-05-06 1999-08-12 Harvard College Rezeptorbindende region des diphtherietoxius
DE69319728T2 (de) 1992-05-23 1999-02-04 Smithkline Beecham Biolog Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
DK0652758T3 (da) 1992-06-18 2000-05-08 Harvard College Diferitoxin-vacciner
ATE254475T1 (de) 1993-09-22 2003-12-15 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FI951970A (fi) 1995-04-25 1996-10-26 Borealis As Olefiinipolymeerit, jotka sisältävät polaarisia ryhmiä, ja menetelmä niiden valmistamiseksi
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof
BR9608114A (pt) 1995-05-04 2000-10-31 Connaught Lab Vacinas de pertussis a celular e processos para preparação das mesmas
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
CA2259415A1 (en) * 1996-07-02 1998-01-08 Connaught Laboratories Limited Multivalent dtp-polio vaccines
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
US6475754B1 (en) 1999-05-14 2002-11-05 University Of Tennessee Research Corporation Polynucleotides encoding Bordatella bronchiseptica fimbrial proteins (FimN), vectors, and expression systems therefor
SK288007B6 (sk) 2000-06-29 2012-10-02 Glaxosmithkline Biologicals S. A. Multivalent vaccine composition, process for its producing, and its use
EP1174505A1 (en) * 2000-06-30 2002-01-23 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur (Poly)peptides for the preparation of vaccines against Bordetella pertussis and/or Bordetella parapertussis, vaccines based upon such (poly)peptides, and antibodies against such peptides
GB0018031D0 (en) 2000-07-21 2000-09-13 Microbiological Res Authority Improvements relating to vaccines containing bordetella pertussis antigen
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
PT2097102E (pt) 2006-09-07 2012-08-03 Glaxosmithkline Biolog Sa Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
PE20100366A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
PL2454364T3 (pl) 2009-07-16 2014-09-30 Crucell Holland Bv Produkcja wirusa polio o wysokim mianie do produkcji szczepionki
JP6191082B2 (ja) 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム より低用量の抗原および／またはアジュバントを有する混合ワクチン

Also Published As

Publication number Publication date
WO2014135651A1 (en) 2014-09-12
AU2014224556A1 (en) 2015-09-17
US8916173B2 (en) 2014-12-23
US20150086586A1 (en) 2015-03-26
JP2016510056A (ja) 2016-04-04
EA030749B1 (ru) 2018-09-28
JP6282673B2 (ja) 2018-02-21
CA2903937A1 (en) 2014-09-12
BR112015021523A8 (pt) 2021-06-29
SG11201506858SA (en) 2015-09-29
MX2015011879A (es) 2016-01-08
EP2863943B1 (en) 2016-07-13
AU2014224556B2 (en) 2016-10-06
MY172181A (en) 2019-11-15
TWI630915B (zh) 2018-08-01
ES2597832T3 (es) 2017-01-23
AP2015008702A0 (en) 2015-09-30
KR20150124973A (ko) 2015-11-06
TW201440786A (zh) 2014-11-01
EA201591663A1 (ru) 2016-01-29
KR102236498B1 (ko) 2021-04-06
US20140255446A1 (en) 2014-09-11
EP2863943A1 (en) 2015-04-29
CL2015002513A1 (es) 2016-05-27
BR112015021523A2 (pt) 2017-07-18
PH12015501875A1 (en) 2015-12-07
CN105007936B (zh) 2018-10-02
IL241271A (en) 2016-07-31
IL241271A0 (en) 2015-11-30
PE20151720A1 (es) 2015-12-10
CA2903937C (en) 2021-11-09
DK2863943T3 (en) 2016-11-07
CN105007936A (zh) 2015-10-28
NZ630868A (en) 2017-02-24

Similar Documents

Publication Publication Date Title
MX362793B (es) Vacuna acelular contra pertussis.
CL2018000319A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
MX2017009308A (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
PH12017502233A1 (en) Formulations for neoplasia vaccines and methods of preparing thereof
TR201802380T4 (tr) Benzonaftiridin içeren aşılar.
EA202090699A2 (ru) Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
MX2014010417A (es) Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
MX364800B (es) Tilmicosina de accion prolongada mejorada y el uso de la misma en el tratamiento del complejo respiratorio bovino (crb) y en el periodo de la vaca seca.
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
MX2017013564A (es) Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual.
MX2020005584A (es) Vacunacion con particulas de replicon y adyuvante oleoso.
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
PL404247A1 (pl) Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
ES2503516R1 (es) Complejo inmunogénico para vacunación y método de obtención
WO2010080188A3 (en) Epitope targeted anthrax vaccine
AR106501A1 (es) Adyuvante y composición de vacuna que lo contiene
AR088908A1 (es) Vacuna
AR095206A1 (es) Vacuna acelular contra pertussis
MX2019013779A (es) Vacuna que comprende toxoides de clostridium.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: EVONIK DEGUSSA GMBH.*

FG Grant or registration